CytomX Therapeutics, Inc.
CTMX
$3.36
$0.010.30%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.42M | 10.26M | 663.00K | 5.96M | 18.66M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.42M | 10.26M | 663.00K | 5.96M | 18.66M |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | 1.42M | 10.26M | 663.00K | 5.96M | 18.66M |
| SG&A Expenses | 7.60M | 10.69M | 6.26M | 6.43M | 6.62M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 25.20M | 29.93M | 25.80M | 21.73M | 19.94M |
| Operating Income | -23.78M | -19.67M | -25.13M | -15.77M | -1.29M |
| Income Before Tax | -20.61M | -18.19M | -26.46M | -14.17M | -91.00K |
| Income Tax Expenses | 60.00K | 59.00K | 54.00K | 58.00K | 63.00K |
| Earnings from Continuing Operations | -20.67M | -18.25M | -26.51M | -14.23M | -154.00K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -20.67M | -18.25M | -26.51M | -14.23M | -154.00K |
| EBIT | -23.78M | -19.67M | -25.13M | -15.77M | -1.29M |
| EBITDA | -23.73M | -19.42M | -24.62M | -15.63M | -939.00K |
| EPS Basic | -0.09 | -0.10 | -0.17 | -0.09 | 0.00 |
| Normalized Basic EPS | -0.06 | -0.06 | -0.09 | -0.05 | 0.00 |
| EPS Diluted | -0.09 | -0.10 | -0.18 | -0.09 | 0.00 |
| Normalized Diluted EPS | -0.06 | -0.06 | -0.09 | -0.05 | 0.00 |
| Average Basic Shares Outstanding | 218.94M | 177.27M | 169.69M | 165.00M | 129.08M |
| Average Diluted Shares Outstanding | 218.94M | 177.27M | 169.69M | 165.00M | 129.08M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |